ORIC Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Portfolio News / By Karina Tin November 17, 2020
RAPT Therapeutics Reports Positive Initial Data From Ongoing Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications Portfolio News / By Karina Tin November 16, 2020
RAPT Therapeutics Reports Third Quarter 2020 Financial Results Portfolio News / By Karina Tin November 16, 2020
NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy Portfolio News / By Karina Tin November 13, 2020
Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress Portfolio News / By Karina Tin November 12, 2020
NGM Bio Provides Business Highlights and Reports Third Quarter 2020 Financial Results Portfolio News / By Karina Tin November 12, 2020
eFFECTOR Announces Dosing of First Breast Cancer Patient with Tomivosertib in Combination with Chemotherapy Portfolio News / By Karina Tin November 12, 2020
ORIC Pharmaceuticals Reports Third Quarter 2020 Financial and Operational Update Portfolio News / By Karina Tin November 5, 2020
